PRLD
Prelude Therapeutics Inc
NASDAQ: PRLD · HEALTHCARE · BIOTECHNOLOGY
$5.23
+22.48% today
Updated 2026-04-30
Market cap
$275.98M
P/E ratio
—
P/S ratio
22.73x
EPS (TTM)
$-1.29
Dividend yield
—
52W range
$1 – $6
Volume
0.4M
Prelude Therapeutics Inc (PRLD) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $-12.95M | $-25.66M | $-46.18M | $-83.53M | $-83.73M | $-107.06M | $-102.89M | $-56.30M |
| Capital expenditures | $529000.00 | $780000.00 | $621000.00 | $2.32M | $3.02M | $3.51M | $764000.00 | $67000.00 |
| Depreciation | — | — | — | — | — | — | — | — |
| Stock-based comp | $180000.00 | $846000.00 | $5.58M | $20.93M | $25.14M | $25.62M | $21.34M | $11.91M |
| Free cash flow | $-13.48M | $-26.45M | $-46.80M | $-85.85M | $-86.75M | $-110.58M | $-103.65M | $-56.37M |
| Investing cash flow | — | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | — | — | — | — | — | — |